{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-252153","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.741536+00:00","generated_at":"2026-05-30T04:44:00.895222+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nuvation Bio reports Q3 net loss of $41.2M, submits NDA for taletrectinib in ROS1+ NSCLC","bullets":["Net loss of $41.2M ($0.15 per share) vs $19.6M ($0.09) in Q3 2023; cash of $549.1M at Sept 30.","NDA for taletrectinib submitted to FDA for line-agnostic full approval in advanced ROS1+ NSCLC; potential launch mid-2025.","Pooled Phase 2 data: 89% ORR in TKI-naïve patients, median DOR 44 months and PFS 46 months; low 7% discontinuation rate.","Appointed Philippe Sauvage as CFO in October; David Hung appointed Chairman, Robert Bazemore lead independent director.","R&D expenses $27.7M (up $9.2M YoY); G&A $19.6M (up $11.8M YoY) driven by AnHeart acquisition costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-252153","json":"https://secwatch.observer/filing/0001193125-24-252153.json","markdown":"https://secwatch.observer/filing/0001193125-24-252153.md","text":"https://secwatch.observer/filing/0001193125-24-252153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524252153/0001193125-24-252153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524252153/d826537d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:44:00.895222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}